Incretin-based Therapy in Chronic Kidney Disease

Advances in Chronic Kidney Disease

Volumn 17, Issue 5, 2010, Pages 439-449

  Pinelli, Nicole R ^a,b,c   Moore, Carol L ^a,b,c   Tomasello, Sarah ^a,b,c  

^a WAYNE STATE UNIVERSITY   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

Chronic kidney disease; Diabetes mellitus; End stage renal disease; Glucagon like peptide 1; Incretins

Indexed keywords

C REACTIVE PROTEIN; CREATININE; EXENDIN 4; GLIPIZIDE; HEMOGLOBIN A1C; LIRAGLUTIDE; SAXAGLIPTIN; SIMVASTATIN; SITAGLIPTIN; SULFONYLUREA;

ABDOMINAL PAIN; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL ASSESSMENT; CREATININE BLOOD LEVEL; DIARRHEA; DIURESIS; DRUG ACCUMULATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; GLOMERULUS FILTRATION; HEADACHE; HUMAN; HYPOGLYCEMIA; KIDNEY CLEARANCE; KIDNEY FUNCTION; KIDNEY INJURY; LIPID BLOOD LEVEL; LIVER FUNCTION TEST; NASUEA; NATRIURESIS; NAUSEA; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RHINOPHARYNGITIS; SALIVATION; SINGLE DRUG DOSE; SODIUM EXCRETION; UPPER RESPIRATORY TRACT INFECTION; WEIGHT REDUCTION;

EID: 77955784570     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2010.06.003     Document Type: Review

References (58)

1. USRDS 2009 Annual Data Report: Atlas of End-Stage Renal Disease in the United States 2009, United States Renal Data System, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853. UK Prospective Diabetes Study (UKPDS) Group.
3. Nathan D.M., Buse J.B., Davidson M.B., et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American diabetes association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203.
4. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular disease. N Engl J Med 2007, 356:2457-2471.
5. Ramirez S.P., Albert J.M., Blayney M.J., et al. Rosiglitazone is associated with mortality in chronic hemodialysis patients. J Am Soc Nephrol 2009, 20:1094-1101.
6. Home P.D., Pocock S.J., Beck-Nielsen H. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial. Lancet 2009, 373:2125-2135.
7. Guan Y., Hao C., Cha D.R., et al. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005, 11:861-866.
8. Flint A., Raben A., Astrup A., et al. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998, 101:515-520.
9. Larsson H., Holst J.J., Ahrén B. Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiol Scand 1997, 160:413-422.
10. Nauck M.A., Wollschläger D., Werner J., et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 1996, 39:1546-1553.
11. Drucker D.J. Glucagon-like peptides. Diabetes 1998, 47:159-169.
12. Deacon C.F., Johnsen A.H., Holst J.J. Degradation of glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995, 44:1126-1131.
13. Parkes D., Jokda C., Smith P., et al. Pharmacokinetic actions of exendin-4 in the rat: Comparison with glucagon-like peptide 1. Drug Dev Res 2001, 53:260-267.
14. Goke R., Fehmann H.C., Linn T., et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39) amide an antagonist at the glucagon-like peptide 1-(7-36) amide receptor of insulin secreting beta cells. J Biol Chem 1993, 268:19650-19655.
15. Herman G.A., Stevens C., Van Dyck K., et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmcol Ther 2005, 78:675-688.
16. DeFronzo R.A., Okerson T., Viswanathan P., et al. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: A randomized, cross-over study. Curr Med Res Opin 2008, 24:2943-2952.
17. Nielsen L.L., Young A.A., Parkes D.G. Pharmacology of exenatide (synthetic exendin-4): A potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004, 117:77-88.
18. Kolterman O.G., Kim D.D., Shen L., et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005, 62:173-181.
19. Byetta (exenatide) prescribing information 2005, Amylin Pharmaceuticals, Inc, San Diego, CA, Revised October 2009.
20. Klonoff D.C., Buse J.B., Nielsen L.L., et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008, 24:275-286.
21. Shen L.Z., Taylor K., Kim D.D., et al. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev 2004, 20:411-417.
22. Linnebjerg H., Kothare P.A., Park S., et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007, 64:317-327.
23. Moreno C., Mistry M., Roman R.J. Renal effects of glucagon-like peptide in rats. Eur J Pharmacol 2002, 434:163-167.
24. Gutzwiller J., Tschopp S., Bock A., et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 2004, 89:3055-3061.
25. Weise W.J., Sivanandy M.S., Block C.L., et al. Exenatide-associated ischemic renal failure. Diabetes Care 2009, 32:e22-e23.
26. Knudsen L.B., Nielsen P.F., Huusfeldt P.O., et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000, 43:1664-1669.
27. Victoza (liraglutide) prescribing information January 2010, Novo Nordisk, Inc, Princeton, NJ.
28. Marre M., Shaw J., Brändle M., et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009, 26:268-278. LEAD-1 SU Study Group.
29. Nauck M., Frid A., Hermansen K., et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009, 32:84-90. LEAD-2 Study Group.
30. Garber A., Henry R., Ratner R., et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): A randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009, 373:473-481. LEAD-3 (Mono) Study Group.
31. Zinman B., Gerich J., Buse J.B., et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009, 32:1224-1230. LEAD-4 Study Investigators.
32. Russell-Jones D., Vaag A., Schmitz O., et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): A randomised controlled trial. Diabetologia 2009, 52:2046-2055. Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group.
33. Buse J.B., Rosenstock J., Sesti G., et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009, 374:39-47. LEAD-6 Study Group.
34. Bjornsdottir I., Olsen A., Larsen U., et al. Metabolism and excretion of the once-daily human GLP-1 analogue liraglutide in healthy subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Diabetolgia 2008, 51(Suppl 1):S356.
35. Jacobsen L.V., Hindsberger C., Robson R., et al. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol 2009, 68:898-905.
36. Januvia (sitagliptin) prescribing information 2009, Merck & Co., Inc, Whitehouse Station, NJ.
37. Onglyza (saxagliptin) prescribing information. Princeton, NJ: Bristol-Myers Squibb Company, and Wilmington, DE: AstraZeneca Pharmaceuticals LP, 2009.
38. Aschner P., Kipnes M.S., Lunceford J.K., et al. Effect of dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006, 29:2632-2637.
39. Charbonnel B., Karasik A., Liu J., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006, 29:2638-2643.
40. Rosenstock J., Brazg R., Andryuk P.J., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: 24 week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006, 28:1556-1568.
41. Raz I., Hanefeld M., Xu L., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006, 49:2564-2571.
42. Goldstein B.J., Feinglos M.N., Lunceford J.K., et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007, 30:1979-1987.
43. Hermansen K., Kipnes M., Luo E., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007, 9:733-745.
44. Nauck M.A., Meininger G., Sheng D., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: A randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007, 9:194-205.
45. Hollander P., Li J., Allen E., et al. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab 2009, 94:4810-4819. CV181-013 Investigators.
46. Rosenstock J., Aguilar-Salinas C., Klein E., et al. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. Curr Med Res Opin 2009, 25:2401-2411. CV181-011 Study Investigators.
47. Chacra A.R., Tan G.H., Apanovitch A., et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: A randomised controlled trial. Int J Clin Pract 2009, 63:1395-1406. CV181-040 Investigators.
48. Jadzinsky M., Pfützner A., Paz-Pacheco E., et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: A randomized controlled trial. Diabetes Obes Metab 2009, 11:611-622. CV181-039 Investigators.
49. DeFronzo R.A., Hissa M.N., Garber A.J., et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009, 32:1649-1655. Saxagliptin 014 Study Group.
50. Rosenstock J., Sankoh S., List J.F. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab 2008, 10:376-386.
51. Dowling T.C., Briglia A.E., Fink J.C. Characterization of hepatic cytochrome P4503A activity in patients with end-stage renal disease. Clin Pharmacol Ther 2003, 73:427-434.
52. Pai A.B., Norenberg J., Boyd A., et al. Effect of intravenous iron supplementation on hepatic cytochrome P450 3A4 activity in hemodialysis patients: A prospective, open-label study. Clin Ther 2007, 29:2699-2705.
53. Bergman A.J., Cote J., Yi B., et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 2007, 30:1862-1864.
54. Chan J.C., Scott R., Arjona Ferreira J.C., et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008, 10:545-555.
55. Kao D.P., Kohrt H.E., Kugler J. Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. Diabet Med 2008, 25:1229-1230.
56. Jacobson T.A. Toward " pain-free" statin prescribing: Clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc 2008, 83:687-700.
57. Bergman A.J., Cote J., Maes A., et al. Effect of sitagliptin on the pharmacokinetics of simvastatin. J Clinical Pharmacol 2009, 49:483-488.
58. Odegaard D., Lane J., Haire C., et al. Sitagliptin use in kidney transplant recipients: Effect on immunosuppressant levels. Diabetes 2009, 58(Suppl 1):A646. (abstract).